Fate Therapeutics Inc (FATE): Cash & Equivalents
$46.63M
As of 2025-12-31
$32.43M
As of 2026-06-30
-8.7%
3-year compound annual growth
-22.6%
5-year compound annual growth
-3.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $46.63M | +29.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $36.06M | -13.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $41.87M | -31.7% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $61.33M | -54.1% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $133.58M | -20.2% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $167.35M | +67.7% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $99.81M | -47.6% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $190.51M | +114.2% | 2021-02-24, Balance as of period end |
| 2017-12-31 | $88.95M | +0.4% | 2020-03-02, Balance as of period end |
| 2016-12-31 | $88.61M | +36.7% | 2019-03-05, Balance as of period end |
| 2015-12-31 | $64.81M | +32.0% | 2018-03-05, Balance as of period end |
| 2014-12-31 | $49.10M | -9.1% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $54.04M | +494.7% | 2016-03-03, Balance as of period end |
| 2012-12-31 | $9.09M | +42.3% | 2015-03-12, Balance as of period end |
| 2011-12-31 | $6.39M | -43.1% | 2014-03-17, Balance as of period end |
| 2010-12-31 | $11.22M | n/a | 2014-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
| Curis Inc (CRIS) | 2025-12-31 | $5.06M | -74.7% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $63.03M | -65.5% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $319.77M | +130.0% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $66.05M | +36.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $152.41M | -14.7% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
Compare FATE, DBVT, CRIS, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗